ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

vorasidenib

Also written as “Vorasidenib”, “AG881” and “AG-881”.

Its studies are mostly in Astrocytoma · Glioma · Leukemia, Myeloid, Acute, led by 5 companies.

Drug pageVorasidenib: every studyMany companies study it; this page follows only the 12 they lead. All 25 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Jul 6, 201512 company-led studies, 4 open or runningNext primary completion: Nov 23, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Agios Pharmaceuticals50 open or runningphase 1since Jul 6, 2015Jul 6, 2015none ahead
Institut de Recherches Internationales Servier (I.R.I.S.)its history only42 open or runningphase 2since Dec 10, 2025Nov 14, 2025Nov 23, 2026phase 1 · NCT07250633
Servierits history only11 open or runningphase 3since Dec 24, 2024Dec 24, 2024none ahead
Servier (Tianjin) Pharmaceuticalits history only11 open or runningno phasesince Apr 29, 2025Apr 29, 2025Apr 2028NCT06969352
Servier Bio-Innovationits history only10 open or runningphase 1since Apr 19, 2023Apr 19, 2023none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jul 6, 2015First study: phase 1 study in Leukemia, Myeloid, AcuteFirst studyNCT02492737 · 46 enrolled · United States, France
  2. Jun 9, 2017Named vorasidenibINNProposed as its International Nonproprietary Name in WHO's List 117 · before, AG881, AG-881
  3. May 21, 2019Phase 1 study in Healthy Male ParticipantsNCT03960502 · 5 enrolled · United States
  4. Jul 3, 2019Phase 1 study in Healthy ParticipantsNCT04015687 · 22 enrolled · United States
  5. Oct 4, 20192 phase 1 studies in Healthy VolunteersNCT04128787, NCT04145128

TargetBeta

IDH1 →IDH2 →read by rule
“An orally available inhibitor of mutated forms of both isocitrate dehydrogenase type 1 (IDH1, IDH1 [NADP+] soluble) in the cytoplasm and type 2 (IDH2, isocitrate dehydrogenase [NADP+], mitochondrial) in the mitochondria, ”NCIt, by rule
“IDH1/IDH2 inhibitor; Isocitrate dehydrogenase [NADP], mitochondrial inhibitor; Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
ranosidenibruleHUTCHMEDphase 37

Studies

All 5 Agios Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04145128Healthy Volunteers · United States1CompletedDec 11, 201932
NCT04128787Healthy Volunteers · United States1CompletedDec 18, 201936
NCT04015687Healthy Participants · United States1CompletedOct 9, 201922
NCT03960502Healthy Male Participants · United States1CompletedSep 7, 20195
NCT02492737Leukemia, Myeloid, Acute · United States, France1CompletedMar 21, 201846

How it is read

Names in the registry

  • “Vorasidenib”, 5 entries
  • “AG881”, 2 entries
  • “AG-881”, 2 entries
  • “Vorasidenib 20mg”, 1 entry
  • “Vorasidenib 40 mg Oral Tablet”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.